Skip to main content
Shanghai Hile Bio-Technology Co.,Ltd logo

Shanghai Hile Bio-Technology Co.,Ltd — Investor Relations & Filings

Ticker · 603718 ISIN · CNE1000022T4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,480 across all filing types
Latest filing 2025-08-27 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603718

About Shanghai Hile Bio-Technology Co.,Ltd

http://www.hile-bio.com/

Shanghai Hile Bio-Technology Co., Ltd. specializes in the research, development, production, and distribution of veterinary biological products. The company focuses on providing comprehensive health solutions for the livestock and poultry sectors. Its core product portfolio includes a wide range of vaccines targeting major animal diseases, such as swine fever, porcine reproductive and respiratory syndrome (PRRS), foot-and-mouth disease, and various avian influenza strains. Utilizing advanced biotechnology and large-scale manufacturing processes, the company operates high-standard production facilities compliant with Good Manufacturing Practice (GMP) requirements. Hile Bio-Technology emphasizes innovation through its dedicated research and development centers, aiming to enhance animal disease prevention and control. The company serves large-scale farming enterprises and veterinary service providers, maintaining a significant presence in the animal health sector through its commitment to product quality and technical support.

Recent filings

Filing Released Lang Actions
海利生物关于取消监事会、变更注册地址和经营范围并修订《公司章程》及部分治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from Shanghai Haili Biotechnology Co., Ltd. regarding corporate governance changes, including the cancellation of the supervisory board, changes to the registered address and business scope, and extensive revisions to the company's articles of association and governance rules. It references compliance with the Company Law of the People's Republic of China, the Shanghai Stock Exchange listing rules, and other regulatory frameworks. The content is focused on governance structure, board and management roles, shareholder rights, and internal company rules rather than financial results or audit opinions. There is no indication of financial statements, audit reports, earnings data, or capital raising activities. The document is not a report publication announcement since it contains substantive content rather than a brief notice. It is not a proxy solicitation or voting results announcement. The primary focus is on governance and management structure and rules. Therefore, the most appropriate classification is Governance Information (CGR).
2025-08-27 Chinese
海利生物关于召开2025年半年度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a 2025 half-year performance explanation meeting (业绩说明会) for investors. It references the prior release of the 2025 half-year report but does not contain the report itself or detailed financial data. The document provides logistics for the meeting, including time, location, participants, and how investors can ask questions. This matches the characteristics of an Investor Presentation (IP) or a Call Transcript (CT) if it were the transcript. However, since this is a notice about the upcoming performance explanation meeting and not the transcript or presentation itself, it is best classified as an Investor Presentation (IP) type document, as it is focused on investor communication about financial results and company performance. The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the best fit is Investor Presentation (IP).
2025-08-27 Chinese
海利生物2024年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an "Annual Equity Distribution Implementation Announcement" for the year 2024 by Shanghai Haili Biotechnology Co., Ltd. It details the dividend per share, relevant dates for dividend distribution, tax treatment, and the shareholder meeting approval date. The content focuses on the announcement of dividend payment details rather than the full annual report or financial statements. The document length is 2353 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Notice of Dividend Amount (DIV).
2025-07-07 Chinese
海利生物关于对上海证券交易所《关于上海海利生物技术股份有限公司2024年年度报告的信息披露监管问询函》的回复公告
Management Reports Classification · 95% confidence The document is a detailed reply from Shanghai Haili Biological Technology Co., Ltd. to an inquiry letter from the Shanghai Stock Exchange regarding the company's 2024 Annual Report. It contains extensive financial data, operational performance analysis, segment reporting, management discussion on business conditions, asset disposals and acquisitions, and future business strategies. The document references the 2024 annual report and provides detailed explanations and supplementary data related to it. The length is substantial (15,000 characters), and it includes actual financial figures and management commentary, not just an announcement or a certification. Therefore, this document is a Management Discussion and Analysis (MDA) type filing, as it provides management's detailed explanation of financial results, business trends, and outlook related to the annual report.
2025-06-27 Chinese
中兴华会计师事务所（特殊普通合伙）关于对上海海利生物技术股份有限公司2024年年度报告的信息披露监管问询函回复的专项核查意见
Regulatory Filings
2025-06-27 Chinese
海利生物董事兼总经理集中竞价减持股份计划期满暨未减持股份结果公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the expiration of a share reduction plan by a director and general manager, including details about the planned and actual share sales (which were zero). It contains no financial statements or report data but is a formal disclosure of insider shareholding transactions and their results. This fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2025-06-13 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.